Wright Medical Group had expected to complete its acquisition of Tornier during the first half of this year. But now that is a "best case scenario," according to a statement from the company. The Federal Trade Commission has extended the waiting period until the deal close in order to give Tornier time to deal with the agency's concerns about its lower extremity products.
Ranbaxy Laboratories may soon be selling its generic minocycline antibacterial drug to Torrent Pharmaceuticals as a condition for U.S. approval for its merger with Sun Pharmaceuticals.
The Federal Trade Commission is urging a Pennsylvania federal court to move forward with its pay-for-delay lawsuit against AbbVie, rejecting the company's arguments that it did not keep a generic version of its testosterone powerhouse AndroGel off the market and contending that the suit meets a precedent set last year by the U.S. Supreme Court.
The U.S. Federal Trade Commission found only one antitrust wrinkle in the combo of the consumer health units of GlaxoSmithKline and Novartis and says it has been ironed out. Novartis will sell its Habitrol nicotine patch business so the new joint venture will not have too much market sway in pricing of nicotine patches in the U.S.
AbbVie may be under fire from the Federal Trade Commission for delaying AndroGel generics, but it won't have to face racketeering claims over its generics-fighting sales tactics.
Even as the FDA is questioning the widespread use of testosterone-boosting drugs for men, the Federal Trade Commission has sued AbbVie and Teva Pharmaceutical Industries for keeping a generic of one out of their reach for years. It is one of the first actions brought by the FTC since the Supreme Court last year said that so-called pay-for-delay deals are not inherently illegal.
In the wake of a Supreme Court ruling that affirmed its anti-pay-to-delay powers, the Federal Trade Commission has launched several new investigations this year, the agency's healthcare chief told Bloomberg. The enforcers are hoping to hit some unlucky pharma company with a $1 billion settlement this year, an FTC official said earlier this year.
The Federal Trade Commission is so fed up with "pay-for-delay" pharma deals, that it's hoping to reach a $1 billion settlement in at least one pharma antitrust case this year. That's the word from Deborah Feinstein, director of the FTC's Bureau of Competition, who revealed the agency's aims at a recent meeting of the American Bar Association's Section of Antitrust Law in Washington, D.C.
Patent settlements between drugmakers and generic manufacturers have drawn even more scrutiny since the U.S. Supreme Court ruled last summer that the Federal Trade Commission has a right to challenge them. At issue are "pay-for-delay" deals, in which manufacturers of branded drugs pay generics challengers to refrain from launching copies until an agreed-upon date.
India also has signed off on Mylan's deal to buy the injectable unit from Strides Arcolab. The company reportedly agreed there to maintain the production of certain drugs in India that Agila currently manufacturers.